A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Exclusion Criteria

• •Previously treated with dasiglucagon (previously referred to as ZP4207)
• •Known or suspected allergy to trial product(s) or related products
• •Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating.
• •History of hypoglycemic events associated with seizures in the last year prior to screening
• •History of severe hypoglycemia in the last month prior to screening
• •Active malignancy within the last 5 years
• •Current bleeding disorder, including anti-coagulant treatment
• •Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor)
• •Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial
• •Clinically significant abnormal ECG at screening as judged by the investigator
• •Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening
• •Surgery or trauma with significant blood loss within the last 2 months prior to screening
• •A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women